U.S. Food and Drug Administration (FDA) Crackdown on Misleading Drug Advertising (2025)

Table of Contents

1. 1. What the U.S. Food and Drug Administration and U.S. Department of Health and Human Services Announced
2. 2. Direct-to-Consumer Ads, the “Brief Summary” and “Adequate Provision” Explained
3. 3. The Letters Sent to Companies
4. 4. The Announced Rule Change
5. 5. Social Media, Influencers and AI Monitoring
6. 6. The Background the Documents Give
7. 7. Two Different Counts of Past Enforcement Letters
8. 8. What the Action Does Not Do
9. 9. Dates and Legal Status as of 11 October 2026
10. 10. How the Action Fits Earlier and Later U.S. Food and Drug Administration Steps
11. 11. Primary Documents
12. Key Research Papers
13. Connections
14. Featured Videos

1. What the U.S. Food and Drug Administration and U.S. Department of Health and Human Services Announced

The U.S. Food and Drug Administration press release, “U.S. Food and Drug Administration Launches Crackdown on Deceptive Drug Advertising,” is dated 9 September 2025. It names three lines of action:

• Letters. “Today, the U.S. Food and Drug Administration is sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.”
• A rule change. “In addition to enforcing existing law, the U.S. Food and Drug Administration is initiating rulemaking to close the ‘adequate provision’ loophole created in 1997,” which the release says drug companies have used “to conceal critical safety risks in broadcast and digital ads.”
• Monitoring. The U.S. Food and Drug Administration “is already implementing AI and other tech-enabled tools to proactively surveil and review drug ads,” and states that it will “aggressively deploy its available enforcement tools.”

U.S. Department of Health and Human Services issued its own release the same day, “U.S. Department of Health and Human Services, U.S. Food and Drug Administration to Require Full Safety Disclosures in Drug Ads,” and a fact sheet, “Ensuring Patient Safety Through Reform of Direct-to-Consumer Pharmaceutical Advertisement Policies.” The fact sheet lists three things the U.S. Food and Drug Administration is doing: rulemaking to remove the 1997 “adequate provision” pathway, “aggressive enforcement of DTC violations,” and expanding oversight to social media promotion.

Both releases quote the U.S. Department of Health and Human Services Secretary, Robert F. Kennedy, Jr.: “Pharmaceutical ads hooked this country on prescription drugs. We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising.” They also quote the U.S. Food and Drug Administration Commissioner, Marty Makary, M.D., M.P.H.: “For far too long, the U.S. Food and Drug Administration has permitted misleading drug advertisements, distorting the doctor-patient relationship and creating increased demand for medications regardless of clinical appropriateness,” adding that “drug companies spend up to 25% of their budget on advertising.”

Back to Table of Contents

2. Direct-to-Consumer Ads, the “Brief Summary” and “Adequate Provision” Explained

Direct-to-consumer (DTC) advertising means prescription-drug promotion aimed at the public rather than at doctors — television and radio commercials, print ads, websites and social-media posts.

The “brief summary.” Section 502(n) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) requires prescription-drug advertising to include, in the words the federal regulatory agenda quotes, “such other information in brief summary relating to side effects, contraindications, and effectiveness as shall be required in regulations.” The U.S. Food and Drug Administration’s regulation implementing that requirement is 21 CFR 202.1. A contraindication is a condition or situation in which a drug is not to be used because the risk outweighs the benefit, as stated in its approved labeling.

“Adequate provision.” The same regulation contains the “adequate provision” language (21 CFR 202.1(e)(1)(i)(B)). Under the approach the U.S. Food and Drug Administration adopted in the late 1990s, a broadcast ad can state the drug’s major risks (a “major-risk statement”) and then make “adequate provision” for viewers to get the full U.S. Food and Drug Administration-approved labeling from another source — the U.S. Department of Health and Human Services documents list a website, a toll-free number or a print insert — instead of reading the full risk information on air. U.S. Department of Health and Human Services calls this a “loophole”; that is U.S. Department of Health and Human Services’s description.

Misbranded. The U.S. Department of Health and Human Services fact sheet explains that false or misleading advertising “makes the drug at issue misbranded,” which is the legal hook for enforcement under the FD&C Act.

Federal rulemaking. Changing a regulation such as 21 CFR 202.1 normally takes a proposed rule (a notice of proposed rulemaking, NPRM) published in the Federal Register, the government’s daily journal of rules and notices; a public comment period through a numbered docket; and then a final rule. An announcement that rulemaking is “initiated” is the first step, not the rule itself.

Back to Table of Contents

3. The Letters Sent to Companies

The documents describe two kinds of letters:

• A letter to every sponsor. The U.S. Department of Health and Human Services fact sheet says the U.S. Food and Drug Administration “will send a letter to every single sponsor of an approved drug or biologic (several thousand companies),” putting them on notice that the U.S. Food and Drug Administration “will be actively enforcing violations of the law, and directing them to remove all non-compliant promotional materials from the market.” A sponsor is the company that holds the approval for a drug or biologic (a medicine made from living cells, such as an antibody). The U.S. Food and Drug Administration press release describes these as “thousands of letters warning pharmaceutical companies to remove misleading ads.”
• Letters about specific ads. The U.S. Food and Drug Administration press release gives “approximately 100 cease-and-desist letters to companies with deceptive ads.” A cease-and-desist letter demands that a company stop a specific practice. The U.S. Department of Health and Human Services fact sheet says the U.S. Food and Drug Administration “will simultaneously issue dozens of enforcement letters related to false and misleading advertising.”

The U.S. Food and Drug Administration’s warning-letter pages dated 9 September 2025 name individual recipients, among them large drug makers and telehealth firms (online services that prescribe medicines after a remote consultation). This page does not name them.

On the legal basis, the U.S. Department of Health and Human Services fact sheet states that “U.S. Food and Drug Administration’s actions here will be based on its existing authority, though the Agency will take a more expansive reading of its authorities in contrast to the overly cautious approach taken by previous administrations.” It adds that if these actions “do not sufficiently alter DTC advertising behavior,” the U.S. Food and Drug Administration “will return to the 1990s paradigm of issuing hundreds of enforcement letters each year.”

Back to Table of Contents

4. The Announced Rule Change

The planned rule appears in the federal regulatory agenda (the Unified Agenda, which lists rules agencies are preparing) as RIN 0910-AJ14, “Transparency in Direct-to-Consumer Advertising,” at the Proposed Rule Stage, first published in the agenda. Its abstract states that the rule “will revise 21 CFR 202.1 to eliminate the option for prescription drug advertisements broadcast through media such as radio or television to fulfill the statutory brief summary requirement in section 502(n)… by disclosing risk, contraindication, and other safety information in another source beyond the advertisement itself.”

According to the agenda entry:

• What it would require. DTC ads broadcast on radio and television would “disclose all relevant risk and safety information to consumers within the confines of the ad itself rather than referring consumers to an external source.”
• What it is not. “This action does not constitute a ban or unreasonable imposition on DTC drug advertising.”
• Classification. “Economically Significant” and a major rule, with the U.S. Food and Drug Administration expecting annual costs above $100 million for at least one year. The entry lists three ways industry could bear the cost: buying more advertising time, giving existing ad time over to the required safety information, or choosing not to advertise.
• Timetable. A notice of proposed rulemaking projected for December 2026.
• Why this option. The entry calls removal of the “adequate provision” pathway the only option to carry out a 9 September 2025 Presidential Memorandum, which it quotes as instructing U.S. Department of Health and Human Services and the U.S. Food and Drug Administration to “take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks… to the extent permitted by applicable law.”

The U.S. Department of Health and Human Services release describes the goal as “the U.S. Food and Drug Administration’s return to the pre-loophole status quo,” and says the change “requires drug advertisers to present factual, uncontroversial statements that are already legally mandated” while “preserving advertisers’ rights to continue to engage in commercial speech.”

Back to Table of Contents

5. Social Media, Influencers and AI Monitoring

The U.S. Food and Drug Administration press release states that “an increasing reliance on digital and social media channels, including undisclosed paid influencer promotion, has blurred the lines among editorial content, user-generated media and pharmaceutical advertising.” It cites a 2024 review in the Journal of Pharmaceutical Health Services Research as finding that 100% of pharmaceutical social-media posts highlight drug benefits while only 33% mention potential harms, and that 88% of advertisements for top-selling drugs are posted by individuals and organizations that do not follow the U.S. Food and Drug Administration’s fair-balance standard. These are the review’s figures as the U.S. Food and Drug Administration reports them.

The U.S. Department of Health and Human Services fact sheet says the U.S. Food and Drug Administration “will close digital loopholes” by extending oversight to all social-media promotional activity, listing:

• influencer partnerships and sponsored content across all platforms;
• algorithm-driven targeted advertising and “dark ads” (ads shown only to selected audiences);
• AI-generated health content and chatbot interactions;
• platform-specific promotional strategies designed to evade detection;
• emerging digital technologies and promotional methods.

The press release restates the existing legal standard any ad must meet: present “a fair balance between a product’s risks and benefits; avoid exaggerating benefits; not create a misleading overall impression; properly disclose financial relationships; and include information regarding major side effects and contraindications.”

Back to Table of Contents

6. The Background the Documents Give

The U.S. Department of Health and Human Services release and fact sheet cite published research and government figures in support of the action. They are reported here as U.S. Department of Health and Human Services states them:

• DTC advertising “drove about 31% of the rise in U.S. drug spending since 1997.” (U.S. Department of Health and Human Services release)
• Patients who asked physicians for an advertised drug “were about 17 times more likely to receive a prescription than those who didn’t.” (U.S. Department of Health and Human Services release; the fact sheet attributes the finding to Canadian and U.S. primary-care surveys by Mintzes and colleagues)
• Brief exposure to statin commercials raised low-risk patients’ odds of a high-cholesterol diagnosis by 16–20% and of starting statins by 16–22%. (fact sheet)
• In a content analysis of TV drug ads, 94% used positive emotional appeals, and a minority gave factual information about the condition’s mechanism (25%), risk factors (16%) or prevalence (16%). (fact sheet)
• A 2024 scoping review of DTC video ads judged 62% of poor scientific quality, 32% useful, 48% misleading and 34% potentially harmful. (fact sheet)
• Prescription drug use among Americans rose from 39% (1988–1994) to 49.9% (2017–2020). (fact sheet, citing U.S. Centers for Disease Control and Prevention (CDC) figures)
• The top ten pharmaceutical companies spent a combined $13.8 billion on advertising and promotion in 2023, and drug companies spent $369.8 million on social-media advertising aimed at consumers in 2020. (fact sheet)
• The Congressional Budget Office estimated in fall 2024 that a 10% increase in DTC advertising is associated with a 1 to 2.3% increase in drug spending. (fact sheet)

The fact sheet also links DTC campaigns to misdiagnosis of attention-deficit/hyperactivity disorder (ADHD) and unnecessary stimulant use, and to patients switching to heavily promoted drugs without added clinical benefit. Several of the papers it cites are listed under Key Research Papers below.

On the history, the U.S. Department of Health and Human Services documents state that until 1997 drug ads had to report full contraindications, boxed warnings and common precautions, and that broadcast drug ads were rare because of the time that information took to read.

Back to Table of Contents

7. Two Different Counts of Past Enforcement Letters

The two primary documents released on 9 September 2025 give different figures for how often the U.S. Food and Drug Administration had acted against drug ads before the crackdown:

• U.S. Food and Drug Administration press release: “The U.S. Food and Drug Administration used to send more than a hundred warning letters each year, and misleading ads were rare. But over time, enforcement waned and the number of warning letters sent to pharmaceutical companies dropped to one in 2023 and zero in 2024.”
• U.S. Department of Health and Human Services fact sheet: “Enforcement letters plummeted from over 130 annually in the late 1990s to just three in 2023.”

The U.S. Food and Drug Administration counts “warning letters” and gives one for 2023; U.S. Department of Health and Human Services counts “enforcement letters” and gives three. Neither document defines its category or explains the difference, so both figures are given here with their sources. Both describe the same trend: from more than a hundred letters a year in earlier decades (the U.S. Food and Drug Administration says “used to send”; U.S. Department of Health and Human Services says the late 1990s) to almost none by 2023–2024.

Six months later, the U.S. Food and Drug Administration’s March 2026 release said the letters sent since September 2025 numbered “more than had been sent over the entire preceding decade” (see section 10).

Back to Table of Contents

8. What the Action Does Not Do

• It does not ban drug advertising. Neither release announces a ban, and the regulatory agenda entry states that the planned rule “does not constitute a ban or unreasonable imposition on DTC drug advertising.” The press release notes that ads “can raise awareness of disease states and beneficial therapies.”
• It did not change the regulation in 2025. The “adequate provision” language in 21 CFR 202.1 remains in force until a final rule replaces it. No proposed rule had been published in the Federal Register as of 11 October 2026.
• It does not create new legal standards for the letters. The fair-balance and disclosure requirements behind the letters already existed; U.S. Department of Health and Human Services says the enforcement rests on the U.S. Food and Drug Administration’s existing authority.
• The planned rule is narrower than the letters. As the agenda describes it, the rule addresses ads broadcast on media such as radio and television; the letters and the social-media oversight concern promotion in any medium.
• It is not a finding about any particular medicine. The letters concern how products are promoted, not whether an approved drug is safe or effective.

Back to Table of Contents

9. Dates and Legal Status as of 11 October 2026

• 9 September 2025: U.S. Food and Drug Administration and U.S. Department of Health and Human Services releases and the U.S. Department of Health and Human Services fact sheet; letters begin; rulemaking announced.
• Unified Agenda: RIN 0910-AJ14 listed at the Proposed Rule Stage with a notice of proposed rulemaking projected for December 2026.
• 3 March 2026: U.S. Food and Drug Administration announces 30 warning letters to telehealth firms over compounded glucagon-like peptide-1 (GLP-1) marketing, as part of the same crackdown.
• Status on 11 October 2026: the letters were sent under existing law; the “adequate provision” rule change is announced, not proposed. A check of the Federal Register for U.S. Food and Drug Administration documents on “adequate provision,” “direct-to-consumer” and “prescription drug advertisements” from 1 January 2025 to 11 October 2026 found no proposed rule, so no public comment docket for it is open.

Back to Table of Contents

10. How the Action Fits Earlier and Later U.S. Food and Drug Administration Steps

1997–1999: the broadcast pathway. The U.S. Food and Drug Administration and U.S. Department of Health and Human Services documents date the “adequate provision” pathway to 1997. The regulatory agenda entry adds that broadcast drug ads had been rare partly because companies had not been told how to meet the adequate-provision requirement, and that “in 1999, U.S. Food and Drug Administration issued a final guidance document” describing the approach now to be removed.

Late 1990s to 2024: falling enforcement. The U.S. Food and Drug Administration and U.S. Department of Health and Human Services figures in section 7 describe more than a hundred letters a year in the 1990s falling to one (U.S. Food and Drug Administration) or three (U.S. Department of Health and Human Services) in 2023, and zero warning letters in 2024 (U.S. Food and Drug Administration).

2025: compounded glucagon-like peptide-1 drugs. Earlier in 2025 the U.S. Food and Drug Administration declared the semaglutide shortage over (see Semaglutide Shortage Ends). Telehealth marketing of compounded glucagon-like peptide-1 drugs later became a focus of the advertising crackdown, as the March 2026 release below shows.

3 March 2026: a second round to telehealth firms. The U.S. Food and Drug Administration announced 30 warning letters to telehealth companies “for making false or misleading claims regarding compounded glucagon-like peptide-1 products offered on their websites.” It called this “the second group of warning letters sent to telehealth firms since the agency launched in September a crackdown on misleading direct-to-consumer pharmaceutical advertisements,” and stated: “Over the past six months, the agency has sent thousands of letters warning pharmaceutical and telehealth firms to remove misleading ads, more than had been sent over the entire preceding decade.” The main violations it named were claims implying sameness with U.S. Food and Drug Administration-approved products, and advertising drugs under the telehealth firm’s own name or trademark without qualification, implying the firm is the compounder. The release adds that compounded drugs are not U.S. Food and Drug Administration-approved and are not the same as generic drugs. The U.S. Food and Drug Administration’s 2026 proposal on compounding these drugs is covered on U.S. Food and Drug Administration Proposal on Compounded Semaglutide and Tirzepatide (2026).

Other 2025 label actions. The same year the U.S. Food and Drug Administration required labeling changes for other drug classes, including long-term opioid use and extended-release attention-deficit/hyperactivity disorder stimulants under age 6. Those are separate actions under the U.S. Food and Drug Administration’s labeling authority, not part of the advertising crackdown.

Back to Table of Contents

11. Primary Documents

1. U.S. Food and Drug Administration (2025). U.S. Food and Drug Administration Launches Crackdown on Deceptive Drug Advertising. U.S. Food and Drug Administration News Release, 9 September 2025 — fda.gov press announcement
2. U.S. Department of Health and Human Services (2025). U.S. Department of Health and Human Services, U.S. Food and Drug Administration to Require Full Safety Disclosures in Drug Ads. U.S. Department of Health and Human Services Press Release, 9 September 2025 — hhs.gov press release
3. U.S. Department of Health and Human Services (2025). Fact Sheet: Ensuring Patient Safety Through Reform of Direct-to-Consumer Pharmaceutical Advertisement Policies. September 2025 — U.S. Department of Health and Human Services fact sheet (archived copy)
4. Office of Information and Regulatory Affairs, Unified Agenda. U.S. Department of Health and Human Services/FDA, RIN 0910-AJ14, Transparency in Direct-to-Consumer Advertising (Proposed Rule Stage; NPRM projected 12/2026; 21 CFR 202) — reginfo.gov RIN 0910-AJ14
5. U.S. Food and Drug Administration (2026). U.S. Food and Drug Administration Warns 30 Telehealth Companies Against Illegal Marketing of Compounded glucagon-like peptide-1 receptor agonists (GLP-1s). U.S. Food and Drug Administration News Release, 3 March 2026 (later status) — fda.gov press announcement

No Federal Register document exists yet for the rule change; there is no FR citation or comment docket to list.

Back to Table of Contents

Key Research Papers

1. Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA (2002). Influence of direct to consumer pharmaceutical advertising and patients’ requests on prescribing decisions: two site cross sectional survey. BMJ 324(7332):278-279 — PubMed PMID: 11823361
2. Niederdeppe J, Byrne S, Avery RJ, Cantor J (2013). Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use. Journal of General Internal Medicine 28(7):886-893 — PubMed PMID: 23463454
3. Applequist J, Ball JG (2018). An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs. Annals of Family Medicine 16(3):211-216 — PubMed PMID: 29760024
4. Schwartz LM, Woloshin S (2019). Medical Marketing in the United States, 1997-2016. JAMA 321(1):80-96 — PubMed PMID: 30620375
5. Franquiz MJ, McGuire AL (2021). Direct-to-Consumer Drug Advertisement and Prescribing Practices: Evidence Review and Practical Guidance for Clinicians. Journal of General Internal Medicine 36(5):1390-1394 — PubMed PMID: 32930939
6. Patel NG, Hwang TJ, Woloshin S, Kesselheim AS (2023). Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021. JAMA Network Open 6(1):e2250991 — PubMed PMID: 36637824
7. DiStefano MJ, Markell JM, Doherty CC, Alexander GC, Anderson GF (2023). Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising. JAMA 329(5):386-392 — PubMed PMID: 36749334

All papers except Schwartz and Woloshin (2019) are cited in the U.S. Department of Health and Human Services fact sheet of September 2025; that paper covers U.S. medical marketing over the period that began with the 1997 broadcast change.

PubMed Topic Searches

1. PubMed: direct-to-consumer advertising of prescription drugs
2. PubMed: DTC advertising, patient requests and prescribing
3. PubMed: pharmaceutical promotion on social media
4. PubMed: FDA warning letters and drug promotion

Back to Table of Contents

Connections

• U.S. Food and Drug Administration Actions of 2025
• U.S. Food and Drug Administration and Regulation
• U.S. Food and Drug Administration Proposal on Compounded Semaglutide and Tirzepatide (2026)
• Semaglutide Shortage Ends (2025)
• Opioid Long-Term Use Label Changes (2025)
• Attention-Deficit/Hyperactivity Disorder Stimulant Label Under Age 6 (2025)
• Glucagon-Like Peptide-1 Receptor Agonists
• U.S. Food and Drug Administration User Fees and Drug Advertising (a practitioner’s views)

Back to Table of Contents

Featured Videos